Cibus, Inc. Announces Pricing of $20.0 Million Public Offering of Class A Common Stock

Cibus (Nasdaq: CBUS) priced an underwritten public offering of 13,333,333 shares of Class A common stock at $1.50 per share, generating gross proceeds of approximately $20.0 million (or $23.0 million if the underwriter fully exercises a 30-day option).

Rhea-AI Summary

Cibus (Nasdaq: CBUS) priced an underwritten public offering of 13,333,333 shares of Class A common stock at $1.50 per share, generating gross proceeds of approximately $20.0 million (or $23.0 million if the underwriter fully exercises a 30-day option).

Board members agreed to purchase 1,000,000 shares. The offering is expected to close on January 30, 2026, with net proceeds intended for working capital and to fund development of weed management traits in rice.

Positive

• Gross proceeds of approximately $20.0 million
• Board purchase of 1,000,000 shares signals insider participation
• Proceeds earmarked to fund rice weed-management trait development

Negative

• Issuance of 13,333,333 new shares will dilute existing shareholders
• Net proceeds reduced by underwriting discounts, commissions, and expenses
• Closing subject to customary conditions; offering may not complete as expected

Argus Jan 29 session

+9.09% close to close Open Argus

Details

News Market Reaction – CBUS

On Jan 29, the day this news came out, CBUS closed 9.09% above the previous close.

Data tracked by StockTitan Argus for the Jan 29 session.

Market Context

On Jan 29, the day this news came out, the stock closed 9.1% above the previous close. A strong posi...

Analysis

On Jan 29, the day this news came out, the stock closed 9.1% above the previous close. A strong positive reaction aligns with the importance of balance-sheet extension for Cibus, which historically relied on equity raises such as the $22.6M and $27.5M offerings in 2025. However, past offering-related headlines usually saw negative moves, so any sharp upside could reflect short-term positioning or perceived de-risking rather than a shift in dilution concerns, and might prove sensitive to follow-on financing needs.

Key Figures

Shares offered: 13,333,333 shares Offering price: $1.50 per share Board participation: 1,000,000 shares +5 more

Shares offered

13,333,333 shares

Class A Common Stock in this underwritten public offering

Offering price

$1.50 per share

Public offering price for Class A Common Stock

Board participation

1,000,000 shares

Shares to be purchased by Board members at the offering price

Over-allotment option

1,999,999 shares

30-day option granted to underwriter to cover over-allotments

Gross proceeds

$20.0 million

Expected gross proceeds before fees and expenses

Max gross proceeds

$23.0 million

If over-allotment option is fully exercised

Offering close date

January 30, 2026

Expected closing date, subject to customary conditions

Current price

$1.76

Pre-news price vs $1.50 offering price

Previous Offering Reports

5 past events · Latest: Jan 28

Same Type 5 events

1. Jan 28

   Proposed equity offering

   24h Move

   -2.2%

   Announcement of proposed underwritten stock offering for working capital and rice traits.

2. Jun 09

   Offering closing

   24h Move

   -0.6%

   Closing of $27.5M common stock offering at $1.75 per share.

3. Jun 05

   Offering pricing

   24h Move

   -34.3%

   Pricing of $27.5M public offering at $1.75 per share.

4. Jun 04

   Proposed offering

   24h Move

   -34.3%

   Proposed public stock offering with chairman interest to purchase shares.

5. Jan 21

   Registered direct deal

   24h Move

   -5.7%

   $22.6M registered direct deal with shares and warrants at $2.50 per share.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, over-allotments, prospectus supplement

3 terms

underwritten public offering financial

"today announced the pricing of an underwritten public offering of 13,333,333 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

over-allotments financial

"option to purchase up to an additional 1,999,999 shares ... to cover over-allotments"

An over-allotment is a temporary extra batch of shares that the underwriters of a stock offering are allowed to sell beyond the original amount, with the right to buy those shares back later. Think of it as spare tickets sold to meet demand and then reclaimed if needed to keep the market orderly; it helps stabilize the stock price after an offering and can affect short-term supply and potential dilution, which matters to investors tracking price and ownership stakes.

prospectus supplement regulatory

"A prospectus supplement describing the terms of the Offering will be filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the pricing of an underwritten public offering of 13,333,333 shares of its Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”), at a public offering price of $1.50 per share (the “Offering”). Members of Cibus’ Board of Directors will purchase 1,000,000 shares of Class A Common Stock in the Offering at the public offering price.

The Company has also granted the underwriter a 30-day option to purchase up to an additional 1,999,999 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the Offering are to be sold by the Company.

The gross proceeds of the Offering will be approximately $20.0 million (or $23.0 million if the underwriter exercises its option to purchase additional shares of Class A Common Stock in full) before deducting underwriting discounts and commissions in the Offering and other estimated expenses payable by the Company. The Offering is expected to close on January 30, 2026, subject to the satisfaction of customary closing conditions. The Company currently intends to use the net proceeds from the Offering for working capital and general corporate purposes, including to fund further development of its weed management traits in Rice and to pay accrued professional expenses for advisory services.

BTIG, LLC is acting as the sole underwriter for the Offering.

This Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273062), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 30, 2023, as amended on October 25, 2023, and declared effective by the SEC on October 27, 2023. A prospectus supplement describing the terms of the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained from BTIG, LLC, at 65 East 55th Street, New York, New York 10022 or by telephone at (212) 593-7555, or by email at ProspectusDelivery@btig.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cibus

Cibus is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus’ proprietary high-throughput gene-editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated closing of the Offering and the expected use of the proceeds from the Offering. Completion of the Offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements made by Cibus’ management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

CIBUS CONTACTS:

INVESTOR RELATIONS
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com

MEDIA RELATIONS
media@cibus.com

Colin Sanford
colin@bioscribe.com
203-918-4347

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key terms of Cibus (CBUS) public offering on January 29, 2026?

Cibus priced 13,333,333 Class A shares at $1.50 per share for gross proceeds of about $20.0 million. According to the company, underwriter BTIG has a 30-day option for 1,999,999 additional shares, and the expected closing date is January 30, 2026.

How much will Cibus (CBUS) raise and what could increase that amount?

The offering will raise approximately $20.0 million before fees, rising to $23.0 million if over-allotment is fully exercised. According to the company, the underwriter’s 30-day option to buy 1,999,999 extra shares would provide the additional $3.0 million.

Why are Cibus (CBUS) using the net proceeds from the January 2026 offering?

Cibus intends to use net proceeds for working capital and general corporate purposes. According to the company, funds will include development of weed management traits in rice and payment of accrued professional advisory expenses.

Did company insiders participate in the Cibus (CBUS) offering and what does that mean?

Yes, members of Cibus’ board will buy 1,000,000 shares at the public offering price. According to the company, this board participation may signal insider support and partially offsets dilution for outside shareholders.

When will the Cibus (CBUS) offering close and who is the underwriter?

The offering is expected to close on January 30, 2026, subject to customary closing conditions. According to the company, BTIG, LLC is acting as the sole underwriter and will distribute the prospectus supplement via the SEC filing.